Publication:
Impact of Corticosteroid on Covid-19 Pneumonia Patients

Simple item page
dc.contributor.authorMishra, Navin Kumar
dc.contributor.authorKarn, Rohit
dc.contributor.authorShrestha, Milan
dc.contributor.authorAcharya, Abhiskar
dc.contributor.authorAcharya, Sunil
dc.contributor.authorDahal, Suresh
dc.contributor.authorNeopane, Arpana
dc.date.accessioned2026-02-02T06:34:52Z
dc.date.available2026-02-02T06:34:52Z
dc.date.issued2024
dc.descriptionNavin Kumar Mishra Department of Pulmonary, Critical Care and Sleep Medicine, Kathmandu Medical College Teaching Hospital Rohit Karn Department of Internal Medicine, Kathmandu Medical College Teaching Hospital Milan Shrestha Department of Internal Medicine, Kathmandu Medical College Teaching Hospital Abhiskar Acharya Department of Internal Medicine, Kathmandu Medical College Teaching Hospital Sunil Acharya Department of Internal Medicine, Kathmandu Medical College Teaching Hospital Suresh Dahal Department of Community Medicine, Kathmandu Medical College Teaching Hospital Arpana Neopane Department of Pulmonary, Critical Care and Sleep Medicine, Kathmandu Medical College Teaching Hospital
dc.description.abstractAbstract: Background: Globally over 704,753890 had COVID -19 Out of which 7,010,681 died compared to 12031 death in Nepal out of1003450 cases Nationwide. Corticosteroids because of their anti- inflammatory effect may have beneficial effect/s on COVID-19 patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. Corticosteroids are a potential therapeutic agent for patients with COVID-19 pneumonia. The RECOVERY (Randomised Trials in COVID-19 Therapy) trial provided data on the mortality benefits of corticosteroids. Aim: The study aims to see the effect of Corticosteroids on COVID-19 patient outcomes concerning disease progression, length of hospital stay, 28-day mortality, and use of resources like Ventilator. Method: Single Hospital-based Prospective observational study among RT-PCR positive for COVID-19 patients admitted at Kathmandu Medical College Teaching Hospital from June 01, 2021 –July 31st, 2021 requiring oxygen therapy. Patients were grouped into either usual care, including symptomatic treatment only, or a group receiving both usual care and Corticosteroid. Results: This study included 160 RT-PCR-positive cases. There were 53 patients with mild symptoms and 107 with moderate symptoms. Patients with mild symptoms who received standard care had an odds ratio of 1.875 for progression to moderate and severe COVID-19 Compared to those who received both standard care and corticosteroid. Similarly, Patients with moderate symptoms who received standard care had an odds ratio of 1.8 for progression to severe and critical COVID-19 Compared to those who received both standard care as well as corticosteroids. Among patients with mild symptoms, the overall use of a ventilator was 35.85 % and mortality was 13.21 %. Similarly, in patients with moderate symptoms at presentation, a ventilator was needed in 33.64 % and mortality was 24.30 %. Conclusion: Though Corticosteroids seem to have a beneficial role in preventing disease progression, they failed to show a statistically significant reduction of ventilator use and mortality benefit amongst groups.
dc.identifierhttps://doi.org/10.3126/nrj.v3i1.69215
dc.identifier.urihttps://hdl.handle.net/20.500.14572/4439
dc.language.isoen_US
dc.publisherNepalese Respiratory Society
dc.subjectCovid-19 pneumonia
dc.subjectCoronavirus
dc.subjectCorticosteroid
dc.subjectVentilator
dc.titleImpact of Corticosteroid on Covid-19 Pneumonia Patients
dc.typeArticle
dspace.entity.typePublication
local.article.typeOriginal Article
oaire.citation.endPage23
oaire.citation.startPage20

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
20-23.pdf
Size:
285.42 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Publications

Connect with us

Nepal Health Research Council © 2026
Ramshah Path, Kathmandu Nepal P.O.Box 7626